VK2735-102 part 2 oral and subcutaneous maintenance
27 evidence topics · 7 sources
Objective
Oral and additional subcutaneous maintenance regimens after subcutaneous induction
Question the company expects Part 2 to answer
Brief summary in the ClinicalTrials.gov record
Location and study date
Initiation in October 2026
Study dates and United States sites in the ClinicalTrials.gov record (both study parts)
| Field | Registry value |
|---|---|
| Recruitment status | “Recruiting” |
| Primary completion (estimated) | “2027-05” |
| Study completion (estimated) | “2027-07” |
| Site 1 city | “Lake Forest” |
| Site 2 city | “Miami” |
Study design
Design announced at initiation, including weekly oral doses
Reason given for not including a weekly oral regimen
Part B in the ClinicalTrials.gov record
Eligibility criteria
Inclusion criteria in the ClinicalTrials.gov record (both study parts)
Exclusion criteria in the ClinicalTrials.gov record (both study parts)
Treatment
Subcutaneous formulation: weekly induction for 21 weeks
Oral formulation: daily maintenance doses up to 55 mg in five arms
Oral formulation: doses named at the top-line call
Subcutaneous formulation: six every-other-week and monthly maintenance arms
Part B treatment arms in the ClinicalTrials.gov record
Interventions in the ClinicalTrials.gov record
| Intervention | Registry description |
|---|---|
| VK2735 | “SC or oral once daily, once weekly, every other week, or monthly” |
| Placebo | “SC or oral once daily or once weekly” |
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Registered primary and secondary outcome measures
Body weight as an exploratory endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment of approximately 195 participants
Estimated enrollment across both parts in the ClinicalTrials.gov record
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary: study limitations
Part 2 of the VK2735-102 study began in October 2026, and no results have been reported; the company expects results in 2027. It is a phase 1 trial in approximately 195 otherwise healthy adults with a body mass index of at least 30 kg/m2, with a 12-week maintenance period after 21 weeks of weekly subcutaneous induction, a primary endpoint of treatment-emergent adverse events, and body weight change as an exploratory endpoint. The documents disagree on the regimens. The initiation release of 6 October 2026 listed “weekly oral doses”, and a correction note issued on 14 October 2026 removed them; the ClinicalTrials.gov record still lists a group receiving VK2735 “orally weekly” and a group receiving placebo “orally once weekly”. The registry describes 6 Part B arms receiving “one of four VK2735 dose regimens or matching placebo regimen”, while the chief executive officer described five oral arms and six subcutaneous arms. The oral doses have not been disclosed; the September 2026 call named 17.5, 27.5, and 55 mg, and the October 2026 call gave a range of about 17 to 55 mg. The registry estimate of 270 participants for both parts is smaller than the sum of the 180 participants randomized in Part 1 and the approximately 195 planned for Part 2.